#### Accepted Manuscript

Title: N-Alkyl- $\alpha$ -amino acids in Nature and their biocatalytic preparation

Authors: Julia F. Hyslop, Sarah L. Lovelock, Allan J.B. Watson, Peter W. Sutton, Gheorghe-Doru Roiban

 PII:
 S0168-1656(19)30011-2

 DOI:
 https://doi.org/10.1016/j.jbiotec.2019.01.006

 Reference:
 BIOTEC 8339

To appear in: Journal of Biotechnology

Received date:22 October 2018Revised date:18 December 2018Accepted date:3 January 2019

Please cite this article as: Hyslop JF, Lovelock SL, Watson AJB, Sutton PW, Roiban G-Doru, N-Alkyl- $\alpha$ -amino acids in Nature and their biocatalytic preparation, *Journal of Biotechnology* (2019), https://doi.org/10.1016/j.jbiotec.2019.01.006

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# *N*-Alkyl-α-amino acids in Nature and their biocatalytic preparation

Julia F. Hyslop,<sup>[a,b,#]</sup> Sarah L. Lovelock,<sup>[c,#]</sup> Allan, J. B. Watson,<sup>[d]</sup> Peter W. Sutton,<sup>\*[e]</sup> and Gheorghe-Doru Roiban<sup>\*[b]</sup>

[a] Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK

[b] Advanced Manufacturing Technologies, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK E-mail: <u>gheorghe.d.roiban@gsk.com</u>

[c] Manchester Institute of Biotechnology, School of Chemistry, University of Manchester, 131Princess Street, Manchester, M1 7DN, UK

[d] EaStCHEM, School of Chemistry, University of St Andrews, North Haugh, St Andrews, Fife, KY16 9ST, UK

[e] Department of Chemical, Biological and Environmental Engineering, Group of Bioprocess
 Engineering and Applied Biocatalysis, Universitat Autònoma de Barcelona, 08193 Bellaterra,
 (Cerdanyola del Vallès), Catalunya, Spain E-mail: <a href="mailto:peter.sutton@uab.cat">peter.sutton@uab.cat</a>

<sup>#</sup>Equal contribution

Highlights

- The *N*-alkyl amino acid moiety is widespread in Nature.
- A number of commercial products related to health contain the *N*-alkylated amino acid moiety.
- Biocatalysis can provide more efficient and sustainable methods of accessing the *N*-alkyl amino acid moiety than traditional methods.
- Several new enzyme classes comprising *N*-methyl transferases and dehydrogenases can be used for the synthesis of *N*-alkyl amino acids.

#### Abstract

*N*-alkylated- $\alpha$ -amino acids are useful building blocks for the pharmaceutical and fine chemical industries. Enantioselective methods of *N*-alkylated- $\alpha$ -amino acid synthesis are therefore highly valuable and widely investigated. While there are a variety of chemical methods for their synthesis,

they often employ stoichiometric quantities of hazardous reagents such as pyrophoric metal hydrides or genotoxic alkylating agents, whereas biocatalytic routes can provide a greener and cleaner alternative to existing methods. This review highlights the occurrence of the *N*-alkyl- $\alpha$ -amino acid motif and its role in nature, important applications towards human health and biocatalytic methods of preparation. Several enzyme classes that can be used to access chiral *N*-alkylated- $\alpha$ -amino acids and their substrate selectivities are detailed.

#### Keywords

N-Alkyl-α-amino acids; Biocatalysis; N-Methyl transferases; Dehydrogenases

#### **1.** The occurrence of *N*-alkyl-α-amino acids

*N*- $\alpha$ -Alkylation represents one mechanism by which nature can modulate the activity of chiral  $\alpha$ -amino acids. The most abundant are N-methyl- $\alpha$ -amino acids, encountered sometimes as the monomer, but more frequently, embedded within complex peptide or non-peptide natural products. Perhaps the most well studied natural N-methyl-a-amino acids are sarcosine (1) (N-methyl-a-L-glycine), N,Ndimethylglycine (2) and betaine (3) (also known as glycine betaine) (Fig. 1). All three metabolites are ubiquitous in nature, produced by plants, animals and microorganisms. Each of these metabolites has valuable biological properties that have been the subject of much interest for potential commercial exploitation. Sarcosine (1), currently used as a dietary supplement and as a non-specific glycine transport inhibitor, also holds promise as an adjuvant therapy with sodium benzoate for the treatment of schizophrenia (Lin et al., 2017) and depression, as recently discussed in a review (Mathew, 2013). N,N-Dimethylglycine (2), which is also used as a dietary supplement, reportedly improves immune responses, acts as an athletic performance enhancer, displays anticonvulsant activity and may have use as an antidepressant in patients with autism (Lee et al., 2017). According to a recent review by Wilcken, glycine betaine (3) is used pharmaceutically in anhydrous form as Cystadane®, an adjunctive treatment for homocystinuria and can offer numerous other benefits to human health such as attenuation of liver injury (Wilcken, 2017).

A broad range of betaines, of which glycine betaine (3) represents just one example, exist in nature and their main function is to act as osmolytes. They are produced in particularly high abundance (up to 4M concentrations) by organisms such as cyanobacteria, lichen, marine algae and salt tolerant plants (Chambers and Lever, 1996). Some examples of naturally occurring betaines include the marine indole alkaloids 5,6-dibromo-L-hypaphorine (4) and plakohypaphorine D (5), which also display antioxidant and antihistaminic activity respectively (Netz and Opatz, 2015).

Ribosomal peptides are of huge importance to the pharmaceutical industry, representing over sixty marketed drugs (Wegmuller and Schmid, 2014; Zompra et al., 2009). These range from short, chemically synthesised peptides of up to twenty residues, to peptides of up to 100 residues that are typically produced using recombinant DNA technology in mammalian, yeast or bacterial host systems. Ribosomal peptides and proteins frequently undergo post-translational modification via a broad variety of transformations (Nesterchuk et al., 2011) and the so-called ribosomally-synthesized and post-translationally-modified peptides (RiPPs) have recently been comprehensively reviewed (Arnison et al., 2013). Post-translational modification at the  $\alpha$ -nitrogen atom of *N*-terminal amino acid residues of linear ribosomal peptides (*N*- $\alpha$ -modification) is a common example of post-translational modification, typically occurring through *N*-acylation and less commonly through *N*-methylation (Ann et al., 1987). The *N*-methylation of side-chain residues of histone proteins has been extensively studied over the past 20 years (Murn and Shi, 2017), whereas the role of methylation in other proteins and peptides, including *N*- $\alpha$ -methylation, is still largely unknown (Clarke, 2013; Erce et al., 2012). However, many of these peptides appear to function by interacting with proteins, often as part of extensive macromolecular complexes such as the epigenome and interactome.

*N*-α-Methylation can have a profound effect on the biological activity of peptides. For example, cypemycin is a naturally occurring bacterial peptide that contains post-translational modifications, including *N*-α-dimethylation and displays potent antimicrobial activity and *in vitro* activity against mouse leukemia cells. Unlike cypemycin, its demethylated counterpart, prepared biosynthetically by deletion of the gene responsible for methylation, was inactive when tested towards growth inhibition of the gram-positive bacterium *Micrococcus luteus* (Claesen and Bibb, 2010). In contrast, with the intention of improving the stability of the antimicrobial peptide Nisin, which is used widely in the food industry, tandem *N*-α-monomethylation and lysine side-chain dimethylation, using the *N*-methyltransferases (NMT) from the cypemycin biosynthetic pathway (CypM), resulted in a trimethylated derivative that displayed a 4 and 8-fold increase in minimum inhibitory concentration (MIC) towards *Lactococcus Lactis* HP (ATCC11602) and *Bacillus subtillis* 168 (ATCC6633) respectively (Zhang and van der Donk, 2012).

Cyclic peptides are important in medicinal chemistry because they offer a number of advantages over acyclic peptides such as improved stability towards proteases, better membrane penetration and reduced toxicity due to enhanced receptor selectivity resulting from reduced conformational flexibility (Ripka et al., 1998). Cyclosporin A (6), which contains seven backbone *N*-methyl groups, represents an excellent example of a conformationally constrained cyclic non-ribosomal peptide (NRP). Approved by the FDA in 1983, it was still one of the top 100 selling brand name drugs in 2016 (Smith et al., 2016), marketed by Allergan under the trade name Restasis.

*N*-Methyl- $\alpha$ -amino acids are also found embedded into small non-peptoidal secondary metabolites. For example, 4-dimethylallyl-L-abrine (7) is a key intermediate in the biosynthesis of ergot alkaloids (Fig. 1) (Rigbers and Li, 2008).




Fig. 1. N-Methylated glycine primary metabolites of the folate cycle.

Alkyl groups other than methyl can also be naturally incorporated into *N*-alkyl- $\alpha$ -amino acids. For example, opines are produced by a wide variety of organisms including bacteria, plants, and animals including humans (Kung and Wagner, 1970; Schrittwieser et al., 2015).

The primary role of opines in many organisms is in anaerobic respiration (Grieshaber et al., 1994). In fact, the opine pathway is thought to be the oldest of four anaerobic respiration pathways, resulting from the high amino acid abundance and low oxygen levels present in primordial times and is still of key importance to organisms, such as marine invertebrates, that inhabit hypoxic environments (Harcet et al., 2013; Livingstone et al., 1983). There has also been extensive investigation into the role of opines in plant cancers, such as crown gall and hairy root disease, where pathogenic bacteria genetically modify plant cells by transferring bacterial plasmids to the plant chromosome, thereby facilitating the production of opines for use as nutrients and reducing microbial competition (Dessaux et al., 1993). The ability of these bacteria to transfer DNA to other organisms has met with significant interest, whereas, to the best of our knowledge there is little information on the bioactivity of opines or opine derivatives themselves.

A number of different opine families exist, most having a structure resulting from the reductive amination of an  $\alpha$ -amino acid with an  $\alpha$ -ketoacid, as typified by octopine (8). However, there are many other classes, such as opines that utilise alternative keto acids, or that utilise sugars rather than keto acids (Fig. 2) (Dessaux et al., 1993). One particularly interesting aspect of opines is that the majority contain one amino acid of common L-(*S*)-stereochemistry and the other with D-(*R*)-stereochemistry, where the unusual D-(*R*)-stereocentre is formed during the enzyme catalysed condensation reaction. However, L,L-(*S*,*S*)-opines, such as L,L-(*S*,*S*)-succinamoprine, have also been identified (Chilton et al., 1985). A more complex example is that of a new class of bacterial opine metallophores, such as staphylopine (9) produced by *Staphylococcus aureus*, that play a key role in pathogenesis by sequestering metals from their host (Song et al., 2018). These are biosynthesised from three amino acids by the action of *R*-selective 3-amino-3-carboxypropyltransferase (nicotianamine synthase) catalysed *N*-alkylation followed by *S*-selective coupling of the resultant product to a further  $\alpha$ -ketoacid by an opine dehydrogenase (McFarlane et al., 2018; McFarlane and Lamb, 2017).




Fig. 2. Some examples of naturally occurring opines.

Other *N*- $\alpha$ -alkyl groups of amino acids seem to be quite rare or are perhaps embedded into biosynthetic pathways that have yet to be elucidated. One such example that has been identified is (*S*)-*N*-carboxyethyl arginine (10) which is an intermediate in the biosynthesis of clavulanic acid (Elson et al., 1993), a commercial  $\beta$ -lactamase inhibitor that is frequently administered with penicillin antibiotics to minimise drug resistance. This unusual functionality is introduced by the rare thiamine diphosphate (ThDP) dependent carboxyethylation of arginine by the N<sup>2</sup>-(2-carboxyethyl)arginine synthase (CEAS) enzyme (Caines et al., 2009).

#### 2. Preparation of N-alkyl-α-amino acids


The chemical synthesis of *N*-alkyl- $\alpha$ -amino acids is usually performed by *N*-alkylation processes, which employ genotoxic alkylating agents, or reductive amination, utilizing stoichiometric quantities of hazardous hydrides which requires complex work-up procedures and the generation of significant waste (Aurelio et al., 2004; Aurelio and Hughes, 2009; Baxter, 2004; Chruma et al., 1997). Various asymmetric reductive amination methods have also been reported (Arceo and Melchiorre, 2012; Chen

et al., 2009a; Kuang and Distefano, 1998; So et al., 2012), but they each suffer from limitations such as narrow substrate range, use of heavy metals, or the requirement to pre-form the imine to avoid ketone reduction (Aurelio et al., 2004). Biocatalysis offers a less hazardous and wasteful alternative to traditional chemical synthetic methods. Therefore, given the wide variety of natural products that contain *N*-alkyl- $\alpha$ -amino acids, it is not surprising that many enzyme classes, such as *N*methyltransferases and several dehydrogenases, have the potential to be used for *N*-alkyl- $\alpha$ -amino acid synthesis. The use of these enzymes for *N*-alkyl- $\alpha$ -amino acid synthesis is an emerging field and is the focus of this section.

#### 2.1. N-methyltransferases

*N*-Methyltransferases (NMT, EC 2.1.1), are ubiquitous in nature and are responsible for the methylation of a broad range of natural products including the *N*- $\alpha$ -methylation of many of the amino acids, peptides and proteins mentioned above.

These enzymes are highly versatile and depending on their function, can be either highly substrate selective or promiscuous, producing mono-, di- or trimethylated products. For example, in mammalian systems, sarcosine (1) is produced by the selective mono-methylation of glycine (11) by *S*-adenosylmethionine (SAM) dependent glycine sarcosine methyltransferase (GSMT), whereas *N*,*N*-dimethyl glycine (2) and glycine betaine (3) are only accessible from choline (Ducker and Rabinowitz, 2017). A similar pathway is followed in most other organisms, but there are some rare examples of bacteria, that inhabit hypersaline environments, which can produce glycine betaine (3) via a sequential 3-step methylation of glycine using GSMT, sarcosine dimethylglycine methyltransferase (SDMT) and dimethylglycine methyltransferase (DMT) respectively (Scheme 1) (Zou et al., 2016).



Scheme 1. Biosynthesis of glycine betaine from glycine by sequencial methylation that is known to occur in some halophilic bacteria.

A few examples of broad substrate spectrum NMTs, that are capable of direct conversion of amino acids to betaines, have also recently been reported. For example, histidine betaine, an intermediate in the biosynthesis of ergothioneine, is produced directly from histidine in *Mycobacterium smegmatis* solely by the histidine betaine synthase, EgtD (Vit et al., 2015). Unfortunately, EgtD only accepts histidine as substrate, but genome searching identified numerous homologues in bacterial and fungal genomes. Based on this search, the EgtD homologue from *Aspergillus nidulans*, recombinantly expressed in *E. coli*, showed a preference for tyrosine, although histidine, dihydroxyphenylalanine and phenylalanine were tolerated with lower efficiency. In contrast, the halophilic methanoarchaeon *Methanohalophilus portucalensis* strain FDF1<sup>T</sup> contains NMTs capable of both stepwise and direct glycine betaine formation (Chen et al., 2009b). Examples of individual NMTs involved in the stepwise conversion and direct conversion of amino acids to betaines have also been heterologously expressed in *E. coli* in an active form (Lai and Lai, 2011).

NMTs involved in the terminal *N*- $\alpha$ -methylation of peptides and proteins are common and are usually promiscuous towards the peptide sequences they accept, often *N*- $\alpha$ -methylating a range of peptides to different extents and sometimes their sidechains as well. For example, CypM, which is the NMT responsible for the introduction of the *N*- $\alpha$ -dimethylation functionality of cypemycin has been demonstrated to methylate a range of short heptapeptides that resemble the *N*-terminus of the natural substrate, as well as the unrelated antimicrobial peptides, nisin and halodracin (Zhang and van der Donk, 2012). However, this is not always the case as demonstrated by the very selective PZN methyltransferase. This enzyme is highly selective towards the *N*- $\alpha$ -dimethylation of the highly posttranslationally modified peptide desmethylplantazolicin to afford plantazolicin (PZN), an antibiocobial peptide with bacteriocidal activity toward strains of *Bacillus anthracis*, the causative agent of anthrax (Lee et al., 2013).

In contrast to ribosomal peptides, NRPs are backbone *N*-methylated by methylation domains at the terminal *N*- $\alpha$ -position of amino acids or peptides, attached to the same non-ribosomal peptide synthase (NRPS) at peptidyl carrier protein (PCP) regions through thioester linkages (Mori et al., 2018). However, with the aim of improving titres, a second mechanism was recently found when investigating the biosynthetic pathway to the fungal metabolite cycloaspeptide E5 (12) that displays interesting insecticidal activity (de Mattos-Shipley et al., 2018). Unexpectedly, the NRPS required directly incorporates *N*-methyl phenylalanine that is pre-formed by an NMT. This allowed the titre of (12) to be greatly increased by direct feeding of *N*- $\alpha$ -phenylalanine to the fermentation. Unfortunately, the NRPS accepted a very narrow range of alternative substrates, although *N*-methyl-para-fluorophenyl alanine was accepted, allowing access to the difluorinated analogue (13) (Fig. 3). Searching the NCBI database for homologues of the cycloaspeptide E NMT gene, *Pscy*A, the same authors rapidly identified a homologue involved in the biosynthesis of the fungal metabolite ditryptophenaline (14). Taking the

same feeding approach, a difluorinated analogue of ditryptophenaline (15) was also prepared, implying that numerous fungal NMTs capable of N- $\alpha$ -methylating amino acids probably exist.




Fig. 3. Some NRPs and their fluorinated analogues that can be prepared through introduction of intact *N*α-methylamino acids to the fermentation process.


SAM and its analogues are expensive to use in stoichiometric quantities, which has hampered the use of NMTs in in-vitro preparative biotransformations. This has led to methods of in-situ generation from cheap materials, such as the tandem use of SalL, an enzyme which catalyses the alkylation of 5'-deoxy-5-chloroadenosine with methionine and its S-alkyl analogues (Sadler et al., 2017). Whereas the use of these approaches is still at an early stage, they hold much promise for the future as methods of green and sustainable *O*-, *N*- and *C*-alkylation.

#### 2.2. Dehydrogenases

While there are many enzymes which can carry out reductive amination using ammonia, few examples are known to employ alkyl amines (Hummel and Groger, 2012; Schrittwieser et al., 2015; Sharma et al., 2017). Classes of enzymes that are now known to perform this transformation include opine dehydrogenases (ODHs), *N*-methyl amino acid dehydrogenases (NMAADHs), ketimine reductases (KIREDs), pyrroline-5-carboxylate reductases (P5CRs) and imine reductases (IREDs), each of which is discussed below.

#### 2.2.1. Opine dehydrogenases


Opine dehydrogenases (ODHs) are oxidoreductases whose natural role is to catalyse the reductive amination of  $\alpha$ -keto acids with amino acids to provide *N*-carboxylalkyl amino acids (Scheme 2), a class of compounds known informally as opines. Octopine dehydrogenase (OcDH, EC 1.5.1.11) was the first ODH to be identified in 1959, when Van Thoai et al. synthetized D-octopine (8) *in vitro* from arginine and pyruvic acid in the presence of various enzyme preparations from marine invertebrates (Van Thoai and Robin, 1959). A decade later the same group purified the NADH dependent OcDH from mussels of *Pecten maximus* (Van Thoai et al., 1969).




Scheme 2. ODH type catalysed reactions.

Other examples have since been identified in the soil bacteria, Agrobacterium tumefaciens (Heidekamp et al., 1983) and Arthrobacter sp. strain 1C (Asano et al., 1989; Dairi and Asano, 1995). Asano et al. assessed the substrate specificity of ODH using various amines against pyruvate as the  $\alpha$ -keto acid. L-Methionine proved to be the favoured substrate followed closely by L-isoleucine, L-valine, Lphenylalanine, L-leucine, L-alanine, L-threonine, L-cysteine, L-serine, glycine and L-asparagine. A few other amino acids such as β-alanine or L-histidine were not tolerated and no product was observed (Asano et al., 1989). The same group also examined the preparative potential of the ODH from Anthrobacter sp. strain 1C and found it to give a different substrate selectivity pattern (Kato et al., 1996). The enzyme was cloned and recombinantly expressed in E. coli and shown to accept a wide range of amino acids as amine donors on reaction with pyruvic acid (Table 1). Interestingly, (S)phenylalaninol (26), a non-zwitterionic amine, was tolerated as the amine donor and to the best of our knowledge, is the only example of a non-amino acid amine donor accepted by a wild-type enzyme of this class. Glyoxylate and 2-ketobutyrate were also accepted when reacted with L-isoleucine and Lvaline, suggesting that the substrate scope could be extended. The reductive amination of this ODH proceeds with high D(R)-stereoselectivity (>99%) that is common to many, but not all enzymes of this class. This is in contrast with the strict L-(S)-selectivity of other enzymes capable of N-alkylating  $\alpha$ amino acids.

## Table 1. Selected substrate specificity of D-(R)-selective opine dehydrogenase from Arthrobacter sp. strain 1C in reaction with pyruvate (16).







ODHs are usually highly substrate specific, as demonstrated by the ODH from *Pecten maximus* which accepts pyruvic acid (16) and arginine as substrates (Smits et al., 2008). Other amino acid donors such as canavanine (25%), cysteine (1.2%), L-alanine (<1%), ornithine (<1%) and norvaline (<1%), display reduced or negligible activity. Another example is the OcDH from *Mytilus galloprovincialis*, which accepts alanine with approximately 10-fold less activity than arginine (88% versus 9%) (Vazquez-Dorado et al., 2011).


In invertebrates there are many types of ODH that have been identified such as alanopine dehydrogenases (EC 1.5.1.17; AlDH) (Storey, 1983);  $\beta$ -alanopine dehydrogenases (EC 1.5.1.26;  $\beta$ -AlDH) (Kan-no et al., 1999; Sato et al., 1987); strombine dehydrogenases (EC 1.5.1.22; StDH) (Dando, 1981) and tauropine dehydrogenases (EC 1.5.1.23; TaDH)(Gaede, 1986). It should be noted that these classifications are based on their preferred substrate specificity, and there is cross reactivity between ODH classes as many of these enzymes accept substrates of other classes, but with lower activities. This can be seen from the work of Sato *et al.* who tested a variety of ODHs from different marine

organisms towards various amino acid donors and demonstrated that most display a range of activities (Sato et al., 1993). AlDHs, for example, primarily operate on alanine. However Storey et al. tested the substrate specificity of AlDH from *Aphrodite aculeata* and found thatseveral other amino acids were accepted, including glycine, serine and threonine, and a relatively broad range of keto acids (Table 2) with varying efficiencies (Storey, 1983).





The value of these enzymes came to the attention of Codexis Inc. as a potential imine reduction platform if the substrate scope could be broadened to include other ketones and amines. They performed extensive engineering on *Anthrobacter sp.* opine dehydrogenase to expand the accepted substrate scope and identified mutants capable to tolerating substrates such as butylamine, cyclopentanone and an expended range of keto acids (Scheme 3) (Chen et al., 2013). However, these findings have not been disclosed outside of a patent and many details, such as the level of activity, enantioselectivity and exact sequences of the enzyme mutants, remain unclear.




11

#### Scheme 3. Examples of reactions carried out by evolved opine dehydrogenases.

#### 2.2.2. N-Methyl amino acid dehydrogenases


*N*-Methyl amino acid dehydrogenases were first discovered in 1970 by Kung and Wagner (Kung and Wagner, 1970). They reported the formation of *N*-methylalanine when cell free extracts of *Pseudomonas* MS were treated with methylamine. In 1975, the same group managed to purify and characterise the enzyme, which they named *N*-methyl amino acid dehydrogenase for its ability to catalyse the reductive amination of pyruvate and methylamine (Scheme 4) (Lin and Wagner, 1975). *N*-Methyl amino acid dehydrogenases (NMAADHs, EC 1.5.1.1 and EC 1.5.1.21) are also known as  $\Delta^1$ -piperideine-2-carboxylate/ $\Delta^1$ -pyrroline-2-carboxylate reductases (dPkAs), Pip2CRs or Pyr2CRs.




Scheme 4. NMAADHs from *Pseudomonas* MS producing *N*-methylalanine.

Substrate and cofactor specificity were also explored to determine whether other keto acids or amine sources could be accepted by the enzyme. When NADPH was substituted with NADH, conversions dropped from 100% to 4% for the reaction of pyruvate with methylamine. Other keto acids such as oxaloacetate and  $\alpha$ -ketobutyrate were tolerated with diminished efficiency (64% and 14% respectively, relative to pyruvate) in the reaction with methylamine, whilst glyoxalate, hydroxypyruvate and  $\alpha$ -ketoglutarate were not tolerated. Ethylamine and dimethylamine were not tolerated as substrates in the presence of pyruvate and crucially, little activity was observed towards ammonia.

Mihara et al. later found that the NMAADH from *Pseudomonas putida* ATCC12633 is also capable of performing the reductive amination between a number of additional  $\alpha$ -keto acids and methylamine (Mihara et al., 2005). After it was cloned and expressed in *E. coli*, the enzyme displayed moderate activity towards fluorinated, aromatic and aliphatic pyruvate derivatives, but hydroxy and branched chain derivatives such as  $\alpha$ -oxoisovalerate (42) were inert, with pyruvate being the best keto acid tested (Table 3).






Keto acid	Relative activity	Keto acid	Relative activity
ОН	100	г Он 38	27
16		30	
ОН	52	но он	6
39		40	
0 41	30	ОН	0
		42	


Table 4 shows the relative activity of *Pseudomonas putida* NMAADH towards the reductive amination of phenylpyruvate (41) with a range of amines, with methylamine (36) being the most effective by a large margin (Mihara et al., 2005). An increase of one carbon to (43) gives a large decrease in activity. As the chain length increases the activity continues to decrease, however the enzyme does tolerate large amines (such as spermidine (49)) to a small degree. Interestingly, this enzyme is inactive with ammonia and therefore does not form primary amines.

Table 4. The relative activity of Pseudomonas putida NMAADH.



Amine	Relative activity	Amine	Relative activity
NH <sub>2</sub> 36	100	NH <sub>2</sub> 43	4.4
CINH <sub>2</sub> 44	0.74	NH <sub>2</sub> 45	0.16
H N 46	0.12	HO-NH <sub>2</sub> 47	<0.06
NH <sub>3</sub> 48	0	$H_{2}N \sim N \sim NH_{2}$	<0.06


In 2004, the Esaki group demonstrated the synthetic utility of this enzyme by successfully producing *N*-methyl-L-phenylalanine on a 1.6 g scale with good yield and high enantiomeric excess by using NMAADH from *Pseudomonas putida* and glucose dehydrogenase from *Bacillus subtilis* (Muramatsu et al., 2004). Further studies from the same group have shown that NMAADHs can also accept a wide range of cyclic imino acids such as  $\Delta^1$ -piperideine-2-carboxylate and  $\Delta^1$ -pyrroline-2-carboxylate (Yasuda et al., 2006). Cyclic imino acids were produced spontaneously from their corresponding  $\alpha$ -keto- $\omega$ -amino acids which, in turn, produced from their corresponding  $\alpha$ , $\omega$ -diamino acids using amino acid oxidases. One of their best examples is highlighted in Scheme 5 where (*S*)-(53) was obtained in high yield tandem use of lysine oxidase and NMAADH.



Scheme 5. Lysine degradation pathway steps incorporating NMAADHs.

Further studies have shown that NMAADHs from *Pseudomonas putida* can reduce a number of 2,3,4,5tetrahydropyridine-6-carboxylate compounds containing oxygen or sulphur within the ring. (Esaki et al., 2008)  $\Delta^1$ -Piperideine-2-carboxylate and  $\Delta^1$ -pyrroline-2-carboxylate reductases have been also demonstrated to be involved in the catabolism of D-lysine and D-proline (Muramatsu et al., 2005). Recently, researchers from GSK have demonstrated that both keto acid and amine substrate scope can be further expanded with excellent enantioselectivities by using NMAADHs from *Pseudomonas putida*, *P. syringae* and *P. fluorescens* (Table 5) (Hyslop et al., 2018).

Table 5. Example of NMAADH catalysed reductive amination.



	Conversions of NMAADHs		
Amine	Pseudomonas	Pseudomonas	Pseudomonas
	putida	syringae	fluorescens
NH <sub>2</sub>	97	98	98
36			
∕_NH <sub>2</sub>	16	6	5
43			
NH <sub>2</sub>	12	6	5
54			
NH <sub>2</sub>	92	52	58
55			
⊳−NH <sub>2</sub>	59	27	29
56	57	21	23


#### 2.2.3. Ketimine reductases

Ketimine reductases (KIREDs, EC 1.5.1.25) are another class of enzyme that can carry out the reductive amination of imino acids. They were first discovered in mammalian tissues such as rat kidney, brain, liver, testes, heart, skeletal muscle and spleen (Meister, 1962; Meister et al., 1957) and rabbit liver (Meister and Buckley, 1957) and have been shown to catalyse the conversion of  $\Delta^1$ -piperideine-2carboxylate and  $\Delta^1$ -pyrroline-2-carboxylate to their corresponding saturated cyclic amino acids (Table 6, Entries 1-2). Even though KIREDs perform the same natural reaction as NMAADHs, they are structurally distinct (Hyslop et al., 2018). Plant extracts from *Pisum sativum* and *Phaseolus radiatus* also catalyse the conversion of Pyr2C (52) to pipecolic acid (53), but detailed studies of the plant tissues were not performed. The activity of the plant extracts was found to be of the same order of magnitude as that observed with rat liver (Meister et al., 1957).

These enzymes, later found to also reside in pig kidney (Nardini et al., 1988a) and in brain  $\mu$ -Crystallin (CRYM) (Hallen et al., 2011), have also been shown to reduce a variety of naturally occurring sulphur containing cyclic imino acids (Table 6). These compounds are found in varying concentrations within the human brain, although the relative activities of KIREDs towards these sulfur containing compounds was not specified (Hallen et al., 2015a).

Interestingly, both NADH and NADPH appear to be accepted equally in the case of pig kidney KIRED and cerebral l-crystallin/KIRED, but NADPH is the preferred cofactor for cerebellum KIRED. All KIREDs display a strict enantio-preference for the formation of L-alkyl- $\alpha$ -amino acids.

#### Table 6. KIRED substrate scope.



Substrate	Enzyme Source	Product	Reference
$\bigcirc$	Mammalian	$\bigcirc$	(Meister and Buckley, 1957)
└N ́СООН	tissues	└ <sub>№</sub> ́соон	(Meister et al., 1957)
52		53	(Meister, 1962)
	Pig kidney		(Nardini et al., 1988a)
	Bovine Crebellum		(Nardini et al., 1988b)
∫ —соон	Mammalian	Сресоон	(Meister and Buckley, 1957)
N	tissues	N H	(Meister et al., 1957)
54		55	(Meister, 1962)
S	CRYM/ Lamb	S	(Hallen et al., 2011)
L OH	forebrain	И ОН	
Ö	Pig kidney	НО	(Nardini et al., 1988a)
56	Bovine Crebellum	57	(Nardini et al., 1988b)
S	Pig kidney	S	(Nardini et al., 1988a)
HO	Bovine	HO	(Nardini et al., 1988b)
 O O	Cerebellum		
58		59	
( s	Pig kidney	s	(Nardini et al., 1988a)
HO		HO	
ö ő	Bovine		(Nardini et al., 1988b)
60	Cerebellum		
		61	
S-S	Cerebellum	S-S	(Hallen et al., 2014)
O UNIN NO			
62		он но 63	

Hallen et al. further extended the substrate scope of the KIREDs by demonstrating that human ketimine reductase/CRYM, recombinantly expressed in *Escherichia coli* and purified, could catalyse the synthesis of four *N*-functionalised L-alkyl- $\alpha$ -amino acids (Table 7) (Hallen et al., 2015b). The relative

rates quoted in Table 7 are shown in comparison to piperideine-2-carboxylate and as can be seen, the rates for the acyclic keto acids are far lower, but still significant.





Table 7. Conversions of N-Functionalised amino acids synthesised using KIRED.


The biocatalytic utility of KIREDs has recently been further demonstrated by Hyslop et al. (2018). Three recombinant KIREDs, which were cloned and expressed well in *E. coli*, were used to prepare a variety of phenylalanine derivatives on reaction with amines such as methylamine, propargylamine and benzylamine with pyruvate (Table 8). Conversions ranged from 32-81% in the case of methyl amine and were low to moderate when propargyl amine was used as amine donor (19-26%). Cyclopropyl amine was also accepted in good conversions (up to 79%) at 10 mM keto acid concentration.

Table 8. Enzymatic reductive amination conversions for phenylpyruvic acid (41) catalysed by KIREDs.



#### 2.2.4. Imine reductases

Imine reductases carry out the reduction of cyclic imines but have also been exploited in reductive amination reactions (Aleku et al., 2017; Cosgrove et al., 2018; Roiban et al.; Roth et al.; Velikogne et al., 2018). Despite the number of diverse IREDs reported, to the best of our knowledge, there is only one example demonstrating activity towards an  $\alpha$ -keto acid. Aleku *et al.* screened the AspRedAm towards multiple substrates including pyruvate (16), in the presence of methylamine and propargylamine (Scheme 6) (Aleku et al., 2017). However, in the presence of a large excess of the amine donor (>4 equivalents) only modest activities were observed of 3% for methylamine (36) and 4% for propargylamine (55).



Scheme 6. IRED catalysed reductive amination of pyruvate (16) with ethylamine (43).

As research into the IRED field continues to expand rapidly, with many examples of new enzymes and evolution projects, it is likely that more effective examples will be identified in the coming years.

#### 2.3. Other enzyme classes

There are a few other examples of some specific enzymes able of forming *N*-functionalized amino acids. Pyrroline-5-carboxylate reductases (P5CRs, EC 1.5.1.2) are a class of enzymes involved in the biosynthesis of proline, which is formed following reduction of pyrroline-5-carboxylate (Singh et al., 2013). They are perhaps the least characterised of the oxido-reductases described in this chapter in spite of their substrate similarity to that of NMAADHs and KIREDs (Yura, 1959). While several P5CR examples have been identified, none have been used in preparative synthesis. The P5CR from *Neurospora crassa* has been recently screened towards a panel of substrates and accepts methylamine, ethylamine, allylamine and propargylamine with conversions varying from 2% up to 82% (Hyslop et al., 2018). While only one enzyme has been demonstrated to have this activity, there is potential to further explore this enzyme class for amino acid synthesis activity.

Ammonia lyases (AL, EC 4.3.1) are enzymes commonly found in plants and fungi, which carry out either the deamination of amino acids to  $\alpha$ , $\beta$ -unsaturated carboxylic acids and ammonia or the reverse amination process (Lovelock and Turner, 2014). These enzymes accept ammonia as their amine source, but there are very few examples of any other amines being accepted. Viergutz et al. demonstrated that a wild type PAL (from *P. crispum*) was able to deaminate *N*-methyl phenylalanine (62), but did not carry out the reverse reaction at a detectable rate (Viergutz et al., 2003). Additionally, this PAL did not accept 4-nitro-*N*-methyl phenylalanine or 4-nitro-*N*,*N*-dimethyl phenylalanine in either direction.

Preparation of *N*-substituted aspartic acids via enantiospecific conjugate addition of N-nucleophiles to fumaric acids has been successfully demonstrated by Gani et al. using methylaspartase (Saeed Gulzar et al., 1997). Aspartate ammonia lyase is another enzyme type which proved to be an excellent catalyst for the synthesis of *N*-substituted aspartic acids. In this context Weiner et al. demonstrated the enantioselective AspB-catalyzed addition of methylamine to fumarate (Weiner et al., 2008).

#### **3.** Conclusions

*N*-functionalised amino acids are versatile building blocks for the pharmaceutical and fine chemical industries and are particularly important starting materials for peptide drugs. There are now a variety of preparative biocatalytic options to access these materials in enantiopure form, therefore offering a cleaner and greener alternative to chemical synthetic methods which often employ heavy metal catalysts, toxic reagents, environmentally unfriendly solvents and the extensive use of protecting groups. We anticipate they will supplant current chemical methods as improved, engineered enzyme variants for these transformations become available.

#### 4. Acknowledgements

PWS would like to acknowledge the European Union for his current funding: "This project has received funding from the European Union's Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement No 665919".

#### 5. References

- Aleku, G.A., France, S.P., Man, H., Mangas-Sanchez, J., Montgomery, S.L., Sharma, M., Leipold, F., Hussain, S., Grogan, G., Turner, N.J., 2017. A reductive aminase from *Aspergillus oryzae*. Nat. Chem. 9, 961–969. <u>https://doi.org/10.1038/nchem.2782</u>.
- Ann, S., Steven, C., Catherine, C., Jeff, S., 1987. *N*-terminal methylation of proteins: Structure, function and specificity. FEBS Lett. 220, 8–14. <u>https://doi.org/10.1016/0014-5793(87)80866-9</u>.
- Arceo, E., Melchiorre, P., 2012. A bio-inspired route to α-amino acid derivatives. ChemCatChem 4, 459–461. <u>https://doi.org/10.1002/cctc.201100394</u>.
- Arnison, P.G., Bibb, M.J., Bierbaum, G., Bowers, A.A., Bugni, T.S., Bulaj, G., Camarero, J.A., Campopiano, D.J., Challis, G.L., Clardy, J., Cotter, P.D., Craik, D.J., Dawson, M., Dittmann, E., Donadio, S., Dorrestein, P.C., Entian, K.-D., Fischbach, M.A., Garavelli, J.S., Göransson, U., Gruber, C.W., Haft, D.H., Hemscheidt, T.K., Hertweck, C., Hill, C., Horswill, A.R., Jaspars, M., Kelly, W.L., Klinman, J.P., Kuipers, O.P., Link, A.J., Liu, W., Marahiel, M.A., Mitchell, D.A., Moll, G.N., Moore, B.S., Müller, R., Nair, S.K., Nes, I.F., Norris, G.E., Olivera, B.M., Onaka, H., Patchett, M.L., Piel, J., Reaney, M.J.T., Rebuffat, S., Ross, R.P., Sahl, H.-G., Schmidt, E.W., Selsted, M.E., Severinov, K., Shen, B., Sivonen, K., Smith, L., Stein, T., Süssmuth, R.D., Tagg, J.R., Tang, G.-L., Truman, A.W., Vederas, J.C., Walsh, C.T., Walton, J.D., Wenzel, S.C., Willey, J.M., van der Donk, W.A., 2013. Ribosomally synthesized and post-translationally modified peptide natural products: Overview and recommendations for a universal nomenclature. Nat. Prod. Rep. 30, 108–160. https://doi.org/10.1039/C2NP20085F.
- Asano, Y., Yamaguchi, K., Kondo, K., 1989. A new NAD<sup>+</sup>-dependent opine dehydrogenase from *Arthrobacter sp.* Strain 1C. J. Bacteriol. 171, 4466–4471. <u>https://doi.org/10.1128/jb.171.8.4466-4471.1989.</u>
- Aurelio, L., Brownlee, R.T., Hughes, A.B., 2004. Synthetic preparation of *N*-methyl-α-amino acids. Chem. Rev. 104, 5823–5846. <u>https://doi.org/10.1021/cr030024z</u>.
- Aurelio, L., Hughes, A.B., 2009. Synthesis of *N*-alkyl amino acids. Amino acids, peptides and proteins in organic chemistry. Wiley-VCH Verlag GmbH & Co. KGaA, pp. 245–289. <u>https://doi.org/10.1002/9783527631766.ch6</u>.

- Baxter, E.W.R., Allen B., 2004. Reductive aminations of carbonyl compounds with borohydride and borane reducing reagents. Organic Reactions 59, 1–714. https://doi.org/10.1002/0471264180.or059.01.
- Caines, M.E.C., Sorensen, J.L., Schofield, C.J., 2009. Structural and mechanistic studies on N<sup>2</sup>-(2carboxyethyl)arginine synthase. Biochem. Bioph. Res. Co. 385, 512–517. https://doi.org/10.1016/j.bbrc.2009.05.095.
- Chambers, S.T., Lever, M., 1996. Betaines and urinary tract infections. Nephron 74, 1–10. https://doi.org/10.1159/000189274.
- Chen, C.-X., Jiang, B., Branford-White, C., Zhu, L.-M., 2009a. Enantioselective reductive amination of α-keto acids by papain-based semisynthetic enzyme. Biochemistry 74, 36–40. https://doi.org/10.1134/s0006297909010052.
- Chen, H.C., Steven J.; Nazor, Jovana; Sukumaran, Joly; Smith, Derek; Moore, Jeffrey C.; Hughes, Gregory; Janey, Jacob; Huisman, Gjalt; Novick, Scott; Agard, Nicholas; Alvizo, Oscar; Cope, Gregory; Yeo, Wan Lin; Ng, Stephanie, 2013. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds. In: Office, U.S.P. (Ed.). Codexis Inc., United States of America.
- Chen, S.-Y., Lai, M.-C., Lai, S.-J., Lee, Y.-C., 2009b. Characterization of osmolyte betaine synthesizing sarcosine dimethylglycine *N*-methyltransferase from *Methanohalophilus portucalensis*. Arch. Microbiol. 191, 735-743. <u>https://doi.org/10.1007/s00203-009-0501-z</u>.
- Chilton, W.S., Hood, E., Rinehart, K.L., Chilton, M.-D., 1985. L,L-succinamopine: An epimeric crown gall opine. Phytochemistry 24, 2945–2948. <u>https://doi.org/10.1016/0031-9422(85)80032-7</u>.
- Chruma, J.J., Sames, D., Polt, R., 1997. General method for the synthesis of *N*-methyl amino acids and *N*-alkyl amino esters from o'Donnell's Schiff bases. Tetrahedron Lett. 38, 5085-5086. <u>https://doi.org/10.1016/S0040-4039(97)01132-5</u>.
- Claesen, J., Bibb, M., 2010. Genome mining and genetic analysis of cypemycin biosynthesis reveal an unusual class of posttranslationally modified peptides. Proc. Natl. Acad. Sci. USA 107, 16297– 16302. <u>https://doi.org/10.1073/pnas.1008608107</u>.
- Clarke, S.G., 2013. Protein methylation at the surface and buried deep: Thinking outside the histone box. Trends Biochem. Sci. 38, 243–252. <u>https://doi.org/10.1016/j.tibs.2013.02.004</u>.
- Cosgrove, S.C., Brzezniak, A., France, S.P., Ramsden, J.I., Mangas-Sanchez, J., Montgomery, S.L., Heath, R.S., Turner, N.J., 2018. Imine reductases, reductive aminases, and amine oxidases for the synthesis of chiral amines: Discovery, characterization, and synthetic applications. Method. Enzymol. Academic Press. 608, 131–149. <u>https://doi.org/10.1016/bs.mie.2018.04.022</u>.
- Dairi, T., Asano, Y., 1995. Cloning, nucleotide sequencing, and expression of an opine dehydrogenase gene from *Arthrobacter sp.* Strain 1C. Appl. Environ. Microb. 61, 3169-3171.

- Dando, P.R., 1981. Strombine [N-(carboxymethyl)-D-alanine] dehydrogenase and alanopine [meso-N-(1-carboxyethyl)-alanine] dehydrogenase from the mussel Mytilus edulis L. Biochem. Soc. T. 9, 297–298. <u>https://doi.org/10.1042/bst0090297</u>.
- de Mattos-Shipley, Kate, M.J., Greco, C., Heard, D.M., Hough, G., Mulholland, N.P., Vincent, J.L., Micklefield, J., Simpson, T.J., Willis, C.L., Cox, R.J., Bailey, A.M., 2018. The cycloaspeptides: Uncovering a new model for methylated nonribosomal peptide biosynthesis. Chem. Sci. 9, 4109– 4117. <u>https://doi.org/10.1039/C8SC00717A</u>.
- Dessaux, Y., Petit, A., Tempe, J., 1993. Chemistry and biochemistry of opines, chemical mediators of parasitism. Phytochemistry 34, 31–38. <u>https://doi.org/10.1016/S0031-9422(00)90778-7</u>.
- Ducker, G.S., Rabinowitz, J.D., 2017. One-carbon metabolism in health and disease. Cell Metabolism 25, 27-42. <u>https://doi.org/10.1016/j.cmet.2016.08.009</u>.
- Elson, S.W., Baggaley, K.H., Davison, M., Fulston, M., Nicholson, N.H., Risbridger, G.D., Tyler, J.W., 1993. The identification of three new biosynthetic intermediates and one further biosynthetic enzyme in the clavulanic acid pathway. J. Chem. Soc. Chem. Comm., 1212–1214. https://doi.org/10.1039/C39930001212.
- Erce, M.A., Pang, C.N.I., Hart-Smith, G., Wilkins, M.R., 2012. The methylproteome and the intracellular methylation network. Proteomics 12, 564–586. https://doi.org/10.1002/pmic.201100397.
- Esaki, N., Mihara, H., Hara, M., Ueda, M., 2008. Dehydrogenase and a gene encoding the same. US 7.452,704 B2.
- Gaede, G., 1986. Purification and properties of tauropine dehydrogenase from the shell adductor muscle of the ormer, *Haliotis lamellosa*. Eur. J. Biochem. 160, 311–318. <u>https://doi.org/10.1111/j.1432-1033.1986.tb09973.x</u>.
- Grieshaber, M.K., Hardewig, I., Kreutzer, U., Pörtner, H.-O., 1994. Physiological and metabolic responses to hypoxia in invertebrates. Rev. Physiol. Biochem. P. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 43–147. <u>https://doi.org/10.1007/BFb0030909</u>.
- Hallen, A., Cooper, A.J., Smith, J.R., Jamie, J.F., Karuso, P., 2015a. Ketimine reductase/crym catalyzes reductive alkylamination of alpha-keto acids, confirming its function as an imine reductase. Amino Acids 47, 2457–2461. <u>https://doi.org/10.1007/s00726-015-2044-8</u>.
- Hallen, A., Cooper, A.J.L., Jamie, J.F., Haynes, P.A., Willows, R.D., 2011. Mammalian forebrain ketimine reductase identified as μ-crystallin; potential regulation by thyroid hormones. J. Neurochem. 118, 379–387. <u>https://doi.org/10.1111/j.1471-4159.2011.07220.x</u>.
- Hallen, A., Cooper, A.J.L., Smith, J.R., Jamie, J.F., Karuso, P., 2015b. Ketimine reductase/crym catalyzes reductive alkylamination of α-keto acids, confirming its function as an imine reductase. Amino Acids 47, 2457–2461. <u>https://doi.org/10.1007/s00726-015-2044-8</u>.

- Hallen, A., Jamie, J.F., Cooper, A.J., 2014. Imine reductases: A comparison of glutamate dehydrogenase to ketimine reductases in the brain. Neurochem. Res. 39, 527–541. https://doi.org/10.1007/s11064-012-0964-1.
- Harcet, M., Perina, D., Pleše, B., 2013. Opine dehydrogenases in marine invertebrates. Biochem. Genet. 51, 666–676. <u>https://doi.org/10.1007/s10528-013-9596-7</u>.
- Heidekamp, F., Dirkse, W.G., Hille, J., van Ormondt, H., 1983. Nucleotide sequence of the *Agrobacterium tumefaciens* octopine Ti plasmid-encoded *tmr* gene. Nucleic Acids Research 11, 6211–6223.
- Hummel, W., Groger, H., 2012. Reductive amination of keto acids. Enzyme catalysis in organic synthesis. 1165–1203. <u>https://doi.org/10.1002/9783527639861.ch28</u>.
- Hyslop, J., Lovelock, S.L., Sutton, P., Brown, K.K., Watson, A.J.B., Roiban, G.-D., 2018. Biocatalytic synthesis of chiral *N*-functionalized amino acids. Angew. Chem. Int. Ed. 57, 13821–13824. https://doi.org/10.1002/anie.201806893.
- Kan-no, N., Sato, M., Yokoyama, T., Nagahisa, E., 1999. Occurrence of β-alanine-specific opine dehydrogenase in the muscle of the limpet *Cellana grata* gould (Archaeogastropoda). Comp. Biochem. Phys B 123, 125–136. <u>https://doi.org/10.1016/S0305-0491(99)00031-0</u>.
- Kato, Y., Yamada, H., Asano, Y., 1996. Stereoselective synthesis of opine-type secondary amine carboylic acids by a new enzyme opine dehydrogenase use of recombinant enzymes. J. Mol. Catal. B-Enzym 1, 151–160. <u>https://doi.org/10.1016/1381-1177(95)00011-9</u>.
- Kuang, H., Distefano, M.D., 1998. Catalytic enantioselective reductive amination in a host-guest system based on a protein cavity. J. Am. Chem. Soc. 120, 1072–1073. <u>https://doi.org/10.1021/ja972771h</u>.
- Kung, H.-F., Wagner, C., 1970. The enzymatic synthesis of *N*-methylalanine. BBA-Gen. Subjects 201, 513–516. <u>https://doi.org/10.1016/0304-4165(70)90177-7</u>.
- Lai, S.-J., Lai, M.-C., 2011. Characterization and regulation of the osmolyte betaine synthesizing enzymes GSMT and SDMT from halophilic methanogen *Methanohalophilus portucalensis*. PLoS ONE 6, e25090. <u>https://doi.org/10.1371/journal.pone.0025090</u>.
- Lee, J., Hao, Y., Blair, P.M., Melby, J.O., Agarwal, V., Burkhart, B.J., Nair, S.K., Mitchell, D.A., 2013. Structural and functional insight into an unexpectedly selective *N*-methyltransferase involved in plantazolicin biosynthesis. Proc. Natl. Acad. Sci. USA 110, 12954–12959. https://doi.org/10.1073/pnas.1306101110.
- Lee, M.-Y., Lin, Y.-R., Tu, Y.-S., Tseng, Y.J., Chan, M.-H., Chen, H.-H., 2017. Effects of sarcosine and *N*, *N*-dimethylglycine on NMDA receptor-mediated excitatory field potentials. J. Biomed. Sci. 24, 18. <u>https://doi.org/10.1186/s12929-016-0314-8</u>.
- Lin, C.-Y., Liang, S.-Y., Chang, Y.-C., Ting, S.-Y., Kao, C.-L., Wu, Y.-H., Tsai, G.E., Lane, H.-Y., 2017. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia

patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World J. Biol. Psychiatry 18, 357–368. https://doi.org/10.3109/15622975.2015.1117654.

- Lin, M.C., Wagner, C., 1975. Purification and characterization of *N*-methylalanine dehydrogenase. J. Biol. Chem. 250, 3746–3751.
- Livingstone, D.R., de Zwaan, A., Leopold, M., Marteijn, E., 1983. Studies on the phylogenetic distribution of pyruvate oxidoreductases. Biochem. Syst. Ecol. 11, 415–425. https://doi.org/10.1016/0305-1978(83)90047-9.
- Lovelock, S.L., Turner, N.J., 2014. Bacterial *Anabaena variabilis* phenylalanine ammonia lyase: A biocatalyst with broad substrate specificity. Bioorg. Med. Chem. 22, 5555–5557. https://doi.org/10.1016/j.bmc.2014.06.035.
- Mathew, S.J., 2013. Glycine transporter-I inhibitors: A new class of antidepressant? Biol. Psychiat. 74, 710–11. <u>https://doi.org/10.1016/j.biopsych.2013.08.019</u>.
- McFarlane, J.S., Davis, C.L., Lamb, A.L., 2018. Staphylopine, pseudopaline, and yersinopine dehydrogenases: A structural and kinetic analysis of a new functional class of opine dehydrogenase. J. Biol. Chem. 293, 8009–8019. <u>https://doi.org/10.1074/jbc.RA118.002007</u>.
- McFarlane, J.S., Lamb, A.L., 2017. Biosynthesis of an opine metallophore by *Pseudomonas aeruginosa*. Biochemistry 56, 5967–5971. <u>https://doi.org/10.1021/acs.biochem.7b00804</u>.
- Meister, A., 1962. [120]  $\delta^1$ -piperideine-2-carboxylate and  $\delta^1$ -pyrroline-2-carboxylate reductase:  $\Delta^1$ piperideine-2-carboxylate + dpnh + h<sup>+</sup>  $\rightarrow$  l-pipecolate + dpn<sup>+</sup>  $\delta^1$ -pyrroline-2-carboxylate + dpnh + h<sup>+</sup>  $\rightarrow$  l-proline + dpn<sup>+</sup>. Method. Enzymol. Academic Press, pp. 878-882.
- Meister, A., Buckley, S.D., 1957. Pyridine nucleotide-dependent reduction of the α-keto acid analogue of lysine to L-pipecolic acid. Biochim. Biophys. Acta 23, 202–203. <u>https://doi.org/10.1016/0006-3002(57)90308-6</u>.
- Meister, A., Radhakrishnan, A.N., Buckley, S.D., 1957. Enzymatic synthesis of L-pipecolic acid and L-proline. J. Biol. Chem. 229, 789–800.
- Mihara, H., Muramatsu, H., Kakutani, R., Yasuda, M., Ueda, M., Kurihara, T., Esaki, N., 2005. Nmethyl-L-amino acid dehydrogenase from *Pseudomonas putida*. A novel member of an unusual NAD(P)-dependent oxidoreductase superfamily. FEBS J 272, 1117–1123. https://doi.org/10.1111/j.1742-4658.2004.04541.x.
- Mori, S., Pang, A.H., Lundy, T.A., Garzan, A., Tsodikov, O.V., Garneau-Tsodikova, S., 2018.
  Structural basis for backbone *N*-methylation by an interrupted adenylation domain. Nat. Chem. Biol. 14, 428–430. <u>https://doi.org/10.1038/s41589-018-0014-7</u>.
- Muramatsu, H., Mihara, H., Kakutani, R., Yasuda, M., Ueda, M., Kurihara, T., Esaki, N., 2004. Enzymatic synthesis of *N*-methyl-L-phenylalanine by a novel enzyme, *N*-methyl-L-amino acid dehydrogenase, from *Pseudomonas putida*. Tetrahedron: Asymmetry 15, 2841–2843. <u>https://doi.org/10.1016/j.tetasy.2004.06.030</u>.

- Muramatsu, H., Mihara, H., Kakutani, R., Yasuda, M., Ueda, M., Kurihara, T., Esaki, N., 2005. The putative malate/lactate dehydrogenase from *Pseudomonas putida* is an NADPH-dependent δ<sup>1</sup>-piperideine-2-carboxylate/δ<sup>1</sup>-pyrroline-2-carboxylate reductase involved in the catabolism of D-lysine and D-proline. J. Biol. Chem. 280, 5329–5335. <u>https://doi.org/10.1074/jbc.M411918200</u>.
- Murn, J., Shi, Y., 2017. The winding path of protein methylation research: Milestones and new frontiers. Nat. Rev. Mol. Cell Bio. 18, 517–527. <u>https://doi.org/10.1038/nrm.2017.35</u>.
- Nardini, M., Ricci, G., Caccuri, A.M., Solinas, S.P., Vesci, L., Cavallini, D., 1988a. Purification and characterization of a ketimine-reducing enzyme. Eur. J. Biochem. 173, 689–694. <u>https://doi.org/10.1111/j.1432-1033.1988.tb14053.x</u>.
- Nardini, M., Ricci, G., Vesci, L., Pecci, L., Cavallini, D., 1988b. Bovine brain ketimine reductase. BBA-Protein Struct. M. 957, 286–292. <u>https://doi.org/10.1016/0167-4838(88)90285-3</u>.
- Nesterchuk, M.V., Sergiev, P.V., Dontsova, O.A., 2011. Posttranslational modifications of ribosomal proteins in *Escherichia coli*. Acta Naturae 3, 22–33.
- Netz, N., Opatz, T., 2015. Marine indole alkaloids. Mar. Drugs 13, 4814–4914. https://doi.org/10.3390/md13084814.
- Rigbers, O., Li, S.-M., 2008. Ergot alkaloid biosynthesis in *Aspergillus fumigatus*: Overproduction and biochemical characterization of a 4-dimethylallyltryptophan *N*-methyltransferase. J. Biol. Chem. 283, 26859–26868. <u>https://doi.org/10.1074/jbc.M804979200</u>.
- Ripka, A.S., Bohacek, R.S., Rich, D.H., 1998. Synthesis of novel cyclic protease inhibitors using Grubbs olefin metathesis. Bioorg. Med. Chem. Lett. 8, 357–360. <u>https://doi.org/10.1016/S0960-894X(98)00025-0</u>.
- Roiban, G.-D., Kern, M., Liu, Z., Hyslop, J., Lyn Tey, P., Levine, M.S., Jordan, L.S., Brown, K., Hadi, T., Ihnken, L.A.F., Brown, M.J.B., 2017. Efficient biocatalytic reductive aminations by extending the imine reductase toolbox. ChemCatChem 9, 4475–4479. <u>https://doi.org/10.1002/cctc.201701379</u>.
- Roth, S., Kilgore, M.B., Kutchan, T.M., Müller, M., 2018. Exploiting the catalytic diversity of shortchain dehydrogenases/reductases: Versatile enzymes from plants with extended imine substrate scope. ChemBioChem 19, 1849–1852. <u>https://doi.org/10.1002/cbic.201800291</u>.
- Sadler, J.C., Humphreys, L.D., Snajdrova, R., Burley, G.A., 2017. A tandem enzymatic sp<sup>2</sup>-Cmethylation process: Coupling in situ S-adenosyl-L-methionine formation with methyl transfer. ChemBioChem 18, 992–995. <u>https://doi.org/10.1002/cbic.201700115</u>.
- Saeed Gulzar, M., Akhtar, M., Gani, D., 1997. Preparation of *N*-substituted aspartic acids via enantiospecific conjugate addition of *N*-nucleophiles to fumaric acids using methylaspartase: Synthetic utility and mechanistic implications. J. Chem. Soc. Perk. T. 1, 649–656. <u>https://doi.org/10.1039/A605996A</u>.

- Sato, M., Takahara, M., Kanno, N., Sato, Y., Ellington, W.R., 1987. Isolation of a new opine, β-alanopine, from the extracts of the muscle of the marine bivalve mollusc, *Scapharca broughtonii*. Comp. Biochem. Phys. B 88, 803–806. https://doi.org/10.1016/0305-0491(87)90247-1.
- Sato, M., Takeuchi, M., Kanno, N., Nagahisa, E., Sato, Y., 1993. Distribution of opine dehydrogenases and lactate dehydrogenase activities in marine animals. Comp. Biochem. Phys. B 106, 955–960. https://doi.org/10.1016/0305-0491(93)90057-c.
- Schrittwieser, J.H., Velikogne, S., Kroutil, W., 2015. Biocatalytic imine reduction and reductive amination of ketones. Adv. Synth. Catal. 357, 1655–1685. <u>https://doi.org/10.1002/adsc.201500213</u>.
- Sharma, M., Mangas-Sanchez, J., Turner, N.J., Grogan, G., 2017. NAD(P)H-dependent dehydrogenases for the asymmetric reductive amination of ketones: Structure, mechanism, evolution and application. Adv. Synth. Catal. 359, 2011–2025. <u>https://doi.org/doi:10.1002/adsc.201700356</u>.
- Singh, P., Tiwari, A., Singh, S.P., Asthana, R.K., 2013. Proline biosynthesizing enzymes (glutamate 5kinase and pyrroline-5-carboxylate reductase) from a model cyanobacterium for desiccation tolerance. Physiol. Mol. Biol. Plants 19, 521–528. <u>https://doi.org/10.1007/s12298-013-0186-2</u>.
- Smits, S.H., Mueller, A., Schmitt, L., Grieshaber, M.K., 2008. A structural basis for substrate selectivity and stereoselectivity in octopine dehydrogenase from *Pecten maximus*. J. Mol. Biol. 381, 200–211. <u>https://doi.org/10.1016/j.jmb.2008.06.003</u>.
- So, S.M., Kim, H., Mui, L., Chin, J., 2012. Mimicking nature to make unnatural amino acids and chiral diamines. Eur. J. Org. Chem. 2012, 229–241. <u>https://doi.org/10.1002/ejoc.201101073</u>.
- Song, L., Zhang, Y., Chen, W., Gu, T., Zhang, S-Y, Ji, Q., 2018. Mechanistic insights into staphylopinemediated metal acquisition. Proc. Natl. Acad. Sci. USA, 115, 3942–3947. <u>https://doi.org/10.1073/pnas.1718382115</u>.
- Storey, K.B., 1983. Tissue-specific alanopine dehydrogenase and strombine dehydrogenase from the sea mouse, *Aphrodite aculeata* (polychaeta) J. Exp. Zool. 225, 369–378. <u>https://doi.org/10.1002/jez.1402250304</u>.
- Van Thoai, N., Huc, C., Pho, D.B., Olomucki, A., 1969. Octopine déshydrogénase purification et propriétés catalytiques. Biochim. Biophys. Acta - Enzymology 191, 46–57. https://doi.org/10.1016/0005-2744(69)90313-1.
- Van Thoai, N., Robin, Y., 1959. Métabolisme des dérivés guanidylés: VIII. Biosynthèse de l'octopine et répartition de l'enzyme l'opérant chez les invertebrés. Biochim. Biophys. Acta 35, 446–453. https://doi.org/10.1016/0006-3002(59)90394-4.
- Vazquez-Dorado, S., Sanjuan, A., Comesana, A.S., de Carlos, A., 2011. Identification of octopine dehydrogenase from *Mytilus galloprovincialis*. Comp. Biochem. Phys B 160, 94–103. <u>https://doi.org/10.1016/j.cbpb.2011.07.003</u>.

- Velikogne, S., Resch, V., Dertnig, C., Schrittwieser, J.H., Kroutil, W., 2018. Sequence-based in-silico discovery, characterisation, and biocatalytic application of a set of imine reductases. ChemCatChem 10, 3236–3246. <u>https://doi.org/10.1002/cctc.201800607</u>.
- Viergutz, S., Poppe, L., Tomin, A., Retey, J., 2003. Mechanistic investigation of phenylalanine ammonia lyase by using N-methylated phenylalanines. Helv. Chim. Acta 86, 3601–3612. <u>https://doi.org/10.1002/hlca.200390305</u>.
- Vit, A., Misson, L., Blankenfeldt, W., Seebeck, F.P., 2015. Ergothioneine biosynthetic methyltransferase EgtD reveals the structural basis of aromatic amino acid betaine biosynthesis. ChemBioChem 16, 119–125. <u>https://doi.org/10.1002/cbic.201402522</u>.
- Wegmuller, S., Schmid, S., 2014. Recombinant peptide production in microbial cells. Curr. Org. Chem. 18, 1005–1019. https://doi.org/10.2174/138527281808140616160013.
- Weiner, B., Poelarends, G.J., Janssen, D.B., Feringa, B.L., 2008. Biocatalytic enantioselective synthesis of *N*-substituted aspartic acids by aspartate ammonia lyase. Chem. Eur. J. 14, 10094–10100. <u>https://doi.org/doi:10.1002/chem.200801407</u>.
- Wilcken, B., 2017. Therapeutic targets in homocystinuria due to cystathionine β-synthase deficiency:
  New european guidelines. Expert Opin. Orphan D. 5, 1–3. https://doi.org/10.1080/21678707.2017.1259561.
- Yasuda, M., Ueda, M., Muramatsu, H., Mihara, H., Esaki, N., 2006. Enzymatic synthesis of cyclic amino acids by *N*-methyl-L-amino acid dehydrogenase from *Pseudomonas putida*. Tetrahedron: Asymmetry 17, 1775–1779. <u>https://doi.org/10.1016/j.tetasy.2006.07.005</u>.
- Yura, T.V., Henry J., 1959. Pyrroline-5-carboxylate reductase of *Neurospora crassa*: Partial purification and some properties. J. Biol. Chem. 234, 335–338.
- Zhang, Q and van der Donk, W., 2012. Catalytic promiscuity of a bacterial α-*N*-methyltransferase. FEBS Lett. 586, 3391-3397. <u>https://doi.org/10.1016/j.febslet.2012.07.050</u>.
- Zompra, A.A., Galanis, A.S., Werbitzky, O., Albericio, F., 2009. Manufacturing peptides as active pharmaceutical ingredients. Future Med. Chem. 1, 361–377. <u>https://doi.org/10.4155/fmc.09.23</u>.
- Zou, H., Chen, N., Shi, M., Xian, M., Song, Y., Liu, J., 2016. The metabolism and biotechnological application of betaine in microorganism. Appl. Microbiol. Biotechnol. 100, 3865–3876. https://doi.org/10.1007/s00253-016-7462-3.